10-Q: AirSculpt Reports Q3 Loss Amid Revenue Decline, London Closure

AirSculpt Technologies, Inc. reported a significant net loss and revenue decline in Q3 2025, driven by weaker aesthetics industry performance and strategic impairments, while implementing cost reductions and growth initiatives.

Summary

• Revenue for the three months ended September 30, 2025, decreased by 17.8% to $34.993 million, down from $42.548 million in the prior year period.
• Net loss for the three months ended September 30, 2025, increased to $9.512 million, compared to a net loss of $6.040 million for the same period in 2024.
• For the nine months ended September 30, 2025, revenue decreased by 16.1% to $118.376 million, down from $141.172 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $12.950 million, compared to a net loss of $3.217 million for the same period in 2024.
• The company recorded a $7.137 million loss on impairment of long-lived assets in Q3 2025, including a $4.6 million impairment for a Salesforce implementation project and a $2.3 million impairment related to the planned closure of its London facility.
• Cases performed decreased by 15.2% for the three months and 15.7% for the nine months ended September 30, 2025, compared to the respective prior year periods.
• Adjusted EBITDA for the three months ended September 30, 2025, was $3.039 million, down from $4.666 million in the prior year, with Adjusted EBITDA Margin decreasing to 8.7% from 11.0%.
• Adjusted EBITDA for the nine months ended September 30, 2025, was $12.629 million, down from $18.871 million in the prior year, with Adjusted EBITDA Margin decreasing to 10.7% from 13.4%.
• The company implemented a cost reduction program estimated to eliminate approximately $3.0 million in annual overhead costs and contracted expenses.
• An underwritten public offering in June 2025 generated net proceeds of $13.8 million, used to repay $10.0 million of the term loan and for general corporate purposes.

Sentiment

Score: 3

Explanation: The company's financial performance for Q3 and the nine months ended September 30, 2025, shows significant deterioration, with substantial revenue declines, increased net losses, and operational losses. Impairment charges related to a Salesforce project and the closure of the London facility highlight operational challenges and underperforming assets. While strategic initiatives and cost reductions are in progress, the need for debt covenant modifications and capital raises, coupled with a challenging industry backdrop and increased competition from weight-loss drugs, indicates a highly negative short-to-medium term outlook.

Positives

• Implemented a cost reduction program estimated to eliminate approximately $3.0 million in annual overhead costs and contracted expenses.
• Successfully completed an underwritten public offering, raising $13.8 million in net proceeds, which was used to reduce outstanding debt.
• Launched expanded consumer financing offerings across all centers in the first half of fiscal year 2025.
• Focusing on new product innovation and expanding the pilot program of its skin tightening procedure as a standalone offering.
• Customer acquisition costs for the nine months ended September 30, 2025, slightly decreased to $3,050 per customer from $3,095 in the prior year.

Negatives

• Revenue decreased by 17.8% for the three months and 16.1% for the nine months ended September 30, 2025, primarily due to weaker performance across the broader aesthetics industry.
• Net loss significantly increased to $9.512 million for the three months and $12.950 million for the nine months ended September 30, 2025, compared to prior year periods.
• Operating loss increased to $9.750 million for the three months and $10.553 million for the nine months ended September 30, 2025, from $3.716 million and an operating income of $2.315 million, respectively, in the prior year.
• Adjusted EBITDA and Adjusted EBITDA Margin declined for both the three and nine months ended September 30, 2025.
• Recorded a $7.137 million loss on impairment of long-lived assets in Q3 2025, including a $4.6 million impairment for a Salesforce project and a $2.3 million impairment for the London facility due to its planned closure.
• Customer acquisition costs increased to $3,145 per customer for the three months ended September 30, 2025, from $2,900 in the prior year.
• Working capital deficit increased to $(11.9) million as of September 30, 2025, from $(11.5) million at December 31, 2024.
• The company amended its Credit Agreement to modify financial covenants, indicating financial pressure and a need for more flexible terms.

Risks

• Inability to sell equity or other securities in the future at a time when the company might otherwise wish to effect sales.
• Inability to raise capital on commercially reasonable terms, if at all, with future financings potentially diluting stockholders or restricting business.
• Failure to stabilize same-center performance.
• Inability to optimize marketing investment, go-to-market strategy, and sales process.
• Lack of ability to expand financing options for consumers.
• Unsuccessful further product innovations.
• Failure to operate centers in a cost-effective manner.
• Increased operating expenses due to rising inflation.
• Increased competition in the weight loss and obesity solutions market, including from recent regulatory approval, increased market acceptance, availability, and customer awareness of weight-loss drugs.
• Shortages or quality control issues with third-party manufacturers or suppliers.
• Competition for surgeons.
• Litigation or medical malpractice claims, with potential liabilities exceeding insurance coverage.
• Inability to protect the confidentiality of proprietary information.
• Changes in the laws governing the corporate practice of medicine or fee-splitting.
• Changes in regulatory, macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where facilities are located.
• Business disruption or other losses from natural disasters, war, pandemic, terrorist acts, or political unrest.

Future Outlook

The company is focused on stabilizing revenue growth through strategic priorities including optimizing marketing investment, improving go-to-market and sales strategies, enhancing customer experience, launching expanded consumer financing, and focusing on new product innovation. A cost reduction program is expected to eliminate approximately $3.0 million in annual overhead costs. The remaining portion of the Salesforce software project is anticipated to be completed in the first quarter of fiscal year 2026. The company expects to finalize the liquidation process for its London facility in the fourth quarter of fiscal year 2025 and does not anticipate material future cash expenditures from this closure. The company believes cash generated from operations will be sufficient for working capital, liquidity, and debt payments for at least the next 12 months.

Management Comments

• We are optimizing our marketing investment by spending on techniques that have proven successful and testing new areas such as online video and other social marketing channels under the direction of our Chief Digital Officer.
• We are improving our go-to-market and sales strategies under our Chief Sales Officer, dedicated to strengthening our consultative sales model with enhanced training, improving sales processes, and providing a greater focus on increasing lead generation, consultations, and case conversion.
• We are enhancing our customer experience to ensure we consistently provide premium results, with initiatives launched during Q3 2025 and expected to roll out into fiscal year 2026.
• We launched expanded consumer financing offerings across all of our centers in the first half of fiscal year 2025.
• We are focusing on new product innovation and introducing new services to expand our customer reach, leverage existing infrastructure and surgical expertise, and generate incremental revenues, including by expanding our pilot program of our skin tightening procedure as a standalone offering.

Industry Context

The company's revenue decline is primarily attributed to weaker than expected performance across the broader aesthetics industry. The company also faces increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability, and customer awareness of weight-loss drugs.

Comparison to Industry Standards

• The filing explicitly states that the company's 'same-center case decline is primarily attributed to weaker than expected performance across the broader aesthetics industry,' indicating underperformance relative to general industry trends.
• The company acknowledges 'increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability and customer awareness of weight-loss drugs,' suggesting a challenging competitive landscape that may be impacting its market share and growth.

Management Changes

Corporate Governance

Legal Proceedings

• In the ordinary course of business, the company is involved in pending and threatened legal actions and proceedings, mostly involving claims of medical malpractice related to services provided by professional associations and affiliated physicians.
• The company believes the outcome of current legal actions will not have a material adverse effect on its business, financial condition, results of operations, and cash flows, but outcomes cannot be predicted with certainty.
• Insurance coverage is maintained for professional liability and other claims, but there is no assurance it will be adequate to cover all liabilities.

Related Party Transactions

• Vesey Street Capital Partners, L.L.C., affiliated with two directors and the largest stockholder, purchased an aggregate of 1,000,000 shares in the June 2025 underwritten public offering on the same terms as public purchases.
• Vesey Street Capital Partners, L.L.C. (through affiliated entities) provided a $10.0 million limited guaranty of the company's obligations under the Credit Agreement on March 12, 2025.

Stakeholder Impact

• Shareholders: Experience dilution from the public offering and ATM program, face increased net losses and declining revenue, and are exposed to risks related to the company's ability to stabilize performance and raise capital.
• Employees: Subject to a cost reduction program aimed at eliminating $3.0 million in annual overhead costs, which may impact job security or compensation.
• Customers: May benefit from enhanced customer experience initiatives and expanded consumer financing options, but could be affected by the closure of facilities like the London location.
• Creditors: The Credit Agreement was amended to modify covenants and accelerate maturity, and a $10.0 million principal payment was made, indicating active management of debt obligations, but also underlying financial stress.
• Suppliers: Potential impact from cost reduction programs and changes in operational scale (e.g., paused de novo center openings).

Next Steps

• Finalize the liquidation process for the London facility in the fourth quarter of fiscal year 2025.
• Continue to develop the remaining portion of the Salesforce software project, with anticipated completion in the first quarter of fiscal year 2026.
• Roll out enhanced customer experience initiatives into fiscal year 2026.
• Continue optimizing marketing investment and improving go-to-market and sales strategies.

Key Dates

Recommendation

The company reported significant revenue declines and increased net losses for both the quarter and nine months ended September 30, 2025. Operational challenges include increased customer acquisition costs and impairments related to a Salesforce project and the closure of its London facility due to underperformance. While strategic initiatives and cost reductions are underway, the company's financial health has deteriorated, requiring debt covenant modifications and capital raises. The broader aesthetics industry weakness and increased competition from weight-loss drugs pose substantial headwinds, making the near-term outlook highly uncertain and risky for investors. The current financial deterioration and significant external pressures warrant a 'sell' recommendation.

Keywords

AirSculpt, body contouring, liposuction, aesthetics industry, SEC filing, 10-Q, financial results, net loss, revenue decline, impairment, debt covenants, capital raise, cost reduction, strategic initiatives, medical procedures